Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/96526
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Micallef, Benjamin | - |
dc.contributor.author | Nisticò, Robert | - |
dc.contributor.author | Sarac, Sinan B. | - |
dc.contributor.author | Bjerrum, Ole W. | - |
dc.contributor.author | Butler, Dianne | - |
dc.contributor.author | Sammut Bartolo, Nicolette | - |
dc.contributor.author | Serracino-Inglott, Anthony | - |
dc.contributor.author | Borg, John Joseph | - |
dc.date.accessioned | 2022-05-27T06:38:53Z | - |
dc.date.available | 2022-05-27T06:38:53Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | Micallef, B., Nistico, R. G., Sarac, S. B., Bjerrum, O. W., Butler, D., Sammut-Bartolo, N., ... & Borg, J. J. (2022). The changing landscape of treatment options in childhood acute lymphoblastic leukaemia. Drug Discovery Today, 27(5), 1483-1494. | en_GB |
dc.identifier.uri | https://www.um.edu.mt/library/oar/handle/123456789/96526 | - |
dc.description.abstract | New paediatric acute lymphoblastic leukaemia (ALL) treatments have been developed and innovative products are in the pipeline. However, despite many active clinical trials, bridging bench science to clinical development to authorised medicines remains challenging. Research in first-line treatment continues to focus on multidrug chemotherapy with the potential addition of new targeted molecules being studied. Research in second- and third-line treatment represents a shift from cytotoxic intensification to an area of precision medicine through emergent innovative and immuno-oncology products. The collaborative research model in ALL involving different stakeholders should intensify to facilitate bench-to-bedside clinical translation for the benefit of patients. | en_GB |
dc.language.iso | en | en_GB |
dc.publisher | Elsevier | en_GB |
dc.rights | info:eu-repo/semantics/restrictedAccess | en_GB |
dc.subject | Cancer research | en_GB |
dc.subject | Human genetics | en_GB |
dc.subject | Lymphoblastic leukemia | en_GB |
dc.subject | Lymphoblastic leukemia in children | en_GB |
dc.subject | Lymphoblastic leukemia in children -- Treatment | en_GB |
dc.title | The changing landscape of treatment options in childhood acute lymphoblastic leukaemia | en_GB |
dc.type | article | en_GB |
dc.rights.holder | The copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder. | en_GB |
dc.description.reviewed | peer-reviewed | en_GB |
dc.identifier.doi | 10.1016/j.drudis.2022.01.002 | - |
dc.publication.title | Drug Discovery Today | en_GB |
Appears in Collections: | Scholarly Works - FacM&SPha |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
The changing landscape of treatment options in childhood acute lymphoblastic leukaemia.pdf Restricted Access | 5.02 MB | Adobe PDF | View/Open Request a copy |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.